ArticlePLoS neglected tropical diseases2018
Clinical and microbiologic efficacy of the piperazine-based drug lead MMV665917 in the dairy calf cryptosporidiosis model.
Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 31 citations in OpenAlex.
- Insights into the lifecycle of Cryptosporidium and compounds targeting developmental stages.Current opinion in microbiology · 2026Review
- Article
- Most patients with disorders of gut-brain interaction receive pharmacotherapy with major or moderate drug-gene interactions.Neurogastroenterology and motility · 2024Article
- Apicomplexan parasites are attenuated by low-energy electron irradiation in an automated microfluidic system and protect against infection with Toxoplasma gondii.Parasitology research · 2023Article
- Structure-Activity relationships of replacements for the triazolopyridazine of Anti-Cryptosporidium lead SLU-2633.Bioorganic & medicinal chemistry · 2023Article
- Past, current, and potential treatments for cryptosporidiosis in humans and farm animals: A comprehensive review.Frontiers in cellular and infection microbiology · 2023Review
- Mode of action studies confirm on-target engagement of lysyl-tRNA synthetase inhibitor and lead to new selection marker forFrontiers in cellular and infection microbiology · 2023Article
- Identification of potent anti-Cryptosporidium new drug leads by screening traditional Chinese medicines.PLoS neglected tropical diseases · 2022Article
- Article
- High-Throughput Screening of a Marine Compound Library Identifies Anti-Marine drugs · 2022Article
- Optimization of the Urea Linker of Triazolopyridazine MMV665917 Results in a New Anticryptosporidial Lead with Improved Potency and Predicted hERG Safety Margin.Journal of medicinal chemistry · 2021Article
- Spontaneous Selection ofAntimicrobial agents and chemotherapy · 2021Article
- Bicyclic azetidines kill the diarrheal pathogenScience translational medicine · 2020Article
- Cryptosporidiosis should be designated as a tropical disease by the US Food and Drug Administration.PLoS neglected tropical diseases · 2020Article
- Defining Stage-Specific Activity of Potent New Inhibitors of Cryptosporidium parvum GrowthmBio · 2020Article
- Article
- Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosis.Nature communications · 2019Article
- Piperazine-Derivative MMV665917: An Effective Drug in the Diarrheic Piglet Model of Cryptosporidium hominis.The Journal of infectious diseases · 2019Article
- Recent Breakthroughs and Ongoing Limitations inF1000Research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Cryptosporidiosis causes life-threatening diarrhea in infants, but the best available treatment is only modestly efficacious. Rodents infected with relevant Cryptosporidium species do not develop diarrhea, which complicates drug development. Cryptosporidium parvum infection of dairy calves, however, causes an illness like that seen in infants. Here, the clinical and microbiologic anti-Cryptosporidium efficacy of the piperazine-based compound MMV665917 was demonstrated in neonatal calves. Oral administration of MMV665917 (22 mg/kg once daily) was begun two days after the onset of severe diarrhea and continued for seven days. Treatment resulted in prompt resolution of diarrhea, and reduced total fecal oocyst shedding by ~94%. MMV665917 was useful for treatment, rather than just prophylaxis, since it was safe and effective when administered well after the onset of diarrhea. Furthermore, even though all animals received intensive supportive care, there was a strong trend towards improved secondary health outcomes, including general health, appetite, and dehydration measures amongst treated animals. These data establish MMV665917 as an outstanding lead compound for Cryptosporidium drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.